Align Summit: Cambridge based Quiver Bioscience is developing ASOs for CNS conditions, including programs in the red hot Nav1.7/1.8 pain space

Co-Founder & CEO Graham Dempsey describes the difference between Nav1.7 and 1.8, and why he thinks having an ASO approach will succeed in 1.7 where small molecules have not. Plus, an epilepsy program, and what it is like being an earlier stage company today.

‍